HIF1A and cancer: Growing evidence demonstrates that hypoxia and HIF-1α are valid anti-cancer drug targets [39], [40].Therapeutic compounds specific for hypoxia and HIF-1α, and particularly those with less cytotoxicity, will likely enjoy clinical benefits not shared by the commonly used genotoxic chemo drugs that indiscriminately kill both normal and cancer cells and result in severe side effects and treatment failure.